Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
79 Results for "
RGS
" in MedChemExpress (MCE) Product Catalog:
Products (79)
79 Results for "RGS" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site . CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test .
2
2 Cited Publications
Cat. No.: HY-70075
CAS No.: 620113-73-7
Target:
Research Areas:
CCG-63808 is a selective, reversible RGS4 inhibitor with an IC50 of 10 μM for the Gαo-RGS4 interaction . CCG-63808 enhances the contractile response of lymphatic smooth muscle and potentiates agonist-mediated thoracic duct contraction. CCG-63808 can be used in research related to neuropathic pain and hypertension .
1
1 Cited Publications
Cat. No.: HY-70074
CAS No.: 620112-78-9
Target:
Research Areas:
CCG-63802 is a selective, reversible and allosteric RGS4 inhibitor. CCG-63802 specifically binds to RGS4 and blocks the RGS4-Gαo interaction, with an IC50 value of 1.9 μM .
Cat. No.: HY-U00431
CAS No.: 410074-60-1
Target:
Research Areas:
CCG 203769 is a selective G protein signaling (RGS4) inhibitor, which blocks the RGS4-Gαo protein-protein interaction in vitro with an IC50 of 17 nM.
Cat. No.: HY-175763
CAS No.: 865271-09-6
Target:
Research Areas:
Z55660043 is a Regulator of G protein signaling-14 (RGS14) inhibitor with an IC50 of 2.3 μM. Z55660043 selectively and non-covalently inhibits RGS14 GTPase-accelerating protein (GAP) activity without measurable cytotoxicity. Z55660043 can be used for central nervous system and metabolic disorders research .
Cat. No.: HY-RS11908
Target:
Research Areas:
RGS16 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-169282
CAS No.: 338408-78-9
Target:
Research Areas:
RGS2–Galpha-q interaction-IN-1 (Compound AJ-3) is an inhibitor of the RGS2-Galpha-q interaction. RGS2–Galpha-q interaction-IN-1 can inhibit the growth of cancer cell lines expressing RGS2 and exhibits anti-cell migration properties .
Target:
Research Areas:
BMS-192364 is targeting the Gα-RGS interaction to produce an inactive Gα-RGS complex. BMS-192364 reduces urinary bladder contraction and exert RGS-agonist properties by increasing the action of GAPs on Gq proteins. BMS-192364 inhibits calcium flux .
Cat. No.: HY-171251
CAS No.: 1113116-62-3
Target:
Research Areas:
RGS10 modulator-1 (compound 15) is a potent RGS10 modulator. RGS10 modulator-1 significantly reverses IFNγ-induced RGS10 protein and mRNA expression. RGS10 modulator-1 reverse the IFNγ-induced COX-2 mRNA and iNOS expression .
Cat. No.: HY-RS11902
Target:
Research Areas:
RGS1 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11903
Target:
Research Areas:
RGS10 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11904
Target:
Research Areas:
RGS11 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11905
Target:
Research Areas:
RGS12 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11906
Target:
Research Areas:
RGS13 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11907
Target:
Research Areas:
RGS14 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11909
Target:
Research Areas:
Rgs16 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rgs16 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11910
Target:
Research Areas:
Rgs16 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rgs16 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11911
Target:
Research Areas:
RGS17 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS17 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11912
Target:
Research Areas:
RGS18 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS18 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11913
Target:
Research Areas:
RGS19 Human Pre-designed siRNA Set A contains three designed siRNAs for RGS19 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
